The ceiling price for Sanofi's 'Alprolix,' a new treatment for hemophilia B, is expected to decrease through price-volume agreement (PVA) negotiations.

This drug was approved in May 2017, and reimbursement listed in June of the following year.

According to industry sources on December 18, the National Health Insurance Service (NHIS) and Sanofi-Aventis Korea agreed on Alprolix's PVA negotiations (TYPE-NA).

Alprolix has been considered for the PVA negotiation for the first time after it was reimbursement listed in June 2018.

The TYPE-NA negotiation is conducted when the ceiling price is adjusted by the TYPE-GA price or when the bill amount of the same p